Dr. Hoss Dowlat, was until recently, Vice-President, Technical, Drug Development Global Strategy Services, responsible for EU, USA, Japan, China, Korea, and Latin America drug development and regulatory submissions at the leading CRO PAREXEL. He was with PAREXEL CONSULTING 2000-2010
and provided a direct consulting service to more than 50 client companies from Europe, America, Canada,
Korea, Japan, and India.
He has over 30 years of experience in the European and North American pharmaceutical industry, 21 years of which have been in regulatory affairs.
His expertise includes regulatory affairs strategy/operations, drug discovery/design and pharmaceutical development, clinical research and medicinal safety. This includes implementing, for clients, recent 2006-2008 requirements on European Paediatric Investigational Plans (PIP) and Risk Management Plans (RMP) to ensure submission compliance and approvals.